Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status by Bras-Gonçalves, R A et al.
913
Human colorectal cancer is the second most frequent cancer in
Western countries, and the third leading cause of death by cancer
in both sexes (Wilke, 1996). Staging of tumour progression
described by Dukes is the main basis for prognosis. For patients
with advanced stage, adjuvant chemotherapy with 5-fluorouracil
(5-FU) has been shown to decrease recurrence and improve
overall survival (Moertel et al, 1990). Depending on 5-FU
regimen, 20–30% of hepatic metastases are sensitive to 5-FU asso-
ciated with leucovorin (de Gramont et al, 1997; Goldberg et al,
1997).
However, the progression of cancer is often associated with a
chemoresistance to agents used as the first-line therapy and an
effective second-line alternative is presently lacking. Thus, new
anticancer drugs are being developed and biological determinants
allowing one to predict response to therapy need to be established.
CPT-11 (Campto®, Irinotecan) (Kunimoto et al, 1987), a semisyn-
thetic water-soluble derivative of camptothecin (Wall et al, 1966),
demonstrated potent anti-tumour activity against experimental
colon cancer tumour models in vivo (Houghton et al, 1995) and
also in phase I (Armand et al, 1995) and more recently, in phase II
trials (Rougier et al, 1997). The anti-tumour activity is exerted
by SN38, a metabolite of CPT-11 (Kaneda et al, 1990), which
selectively inhibits DNA-topoisomerase1 (top1) (Tanizawa et al,
1994). Cytotoxicity is due to the formation of SN38-stabilized
top1 DNA cleavable ternary complexes (Leteurtre et al, 1993),
which impede the DNA-religation reaction (Kjeldsen et al, 1992),
resulting in DNA single-strand breaks. Stabilized cleavable
complexes are rapidly reversible upon lowering of the time of
exposure to CPT-11 (Tanizawa et al, 1995). Elevated top1 protein
levels increase the frequency of cleavable complexes (Pommier,
1996), thereby increasing DNA damage. As a consequence, DNA
single-strand breaks tend to accumulate, and it is most likely that
attempts to replicate and/or repair the damaged DNA enhances the
formation of DNA double-strand breaks (Vamvakas et al, 1997).
Molecular characterization of genetic alterations in CRC led to
the identification of two carcinogenesis pathways. In 85% of
cases, CRC display chromosomal instability, allelic losses at 5q,
17p and 18q, p53 mutations are frequent, they are often left-sided
and of poor prognosis. The second group (15%) is characterized
by genetic instability, with widespread mutations in microsatellite
sequences, a right-sided location and a better prognosis. These
different pathways of carcinogenesis could account for a differen-
tial sensitivity of CRC to CPT-11. Indeed, the TP53 gene encodes
a multifunctional transcription factor that plays a critical role in
cellular response after DNA damage, including G1 arrest followed
by either DNA repair or apoptosis. Cells defective for p53 have a
survival advantage by lacking the apoptotic programme induced
by the toxic effects of anticancer drugs (Fan et al, 1994; Ceraline
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cally more sensitive to many of the commonly used anticancer
agents (Fujiwara et al, 1994; Lowe et al, 1993, 1994; McDonald
and Brown 1998). In MSI+ tumours, defects in mismatch repair
genes could lead to the accumulation of unrepaired or misrepaired
DNA during DNA replication, rendering them more sensitive for
CPT-11 effect.
Other resistance mechanisms to CPT-11 could also be impli-
cated. Overexpression of the multidrug resistance gene product,
P-glycoprotein, encoded by the mdr1 gene has been incriminated
in tumour cell resistance to numerous compounds (Gottesman
et al, 1996). Its role in the lack of sensitivity of tumour cells to
CPT-11 has been described (Jansen et al, 1998). Two groups have
recently shown that colorectal cancers of the colonic mucosa
express the fas receptor (fasR), a cell membrane determinant
which triggers the apoptotic cascade (Meterissian et al, 1997;
Strater et al, 1997), and that camptothecin treatment activated the
fasR in CRC cell lines (Shao et al, 1998). CPT-11, like several
anticancer drugs (Micheau et al, 1997), might be able to render
tumour cells highly susceptible to fasR-dependent apoptosis.
Our aim was to search for genetic alterations and biological
parameters determining the response of CRCs to CPT-11. First, we
evaluated the in vivo response of nine different xenografted CRCs,
which differed in their MSI phenotype and their p53 status. Five of
the nine xenografts were established from tumours in our labora-
tory. Four of the nine xenografts were derived from CRC cell
lines: MSI+/wtp53 (LoVo) and its subclone (X17LoVo) transfected
with a mutp53 expression vector; and MSI–/mutp53 (HT29) and its
subclone (HT29A3) transfected with a dominant wtp53 expression
vector. Second, expression of top1, the target of CPT-11, of mdr1
and of fasR was investigated in these CRC xenografts.
MATERIALS AND METHODS
Human colon cancer tumours and cell lines
Three primary colorectal tumour specimens (TC1, TC7fal and
TC71) and two liver metastases (TC118m and TC124m) were
obtained from patients. After tumour resection, xenografts were
established by subcutaneous (s.c.) implantation into the scapular
area of nude mice. LoVo and HT29 cell lines were obtained from
the American Type Cell Collection (Rockville, MD, USA). The
LoVo cell line (MSI+/wtp53) was previously transfected with an
Ala273-mutp53 geneticin resistance expression vector, as
described (Pocard et al, 1996), producing the X17LoVo subclone
which had stable integrated the plasmid. LoVo was arrested in the
G1 phase of the cell cycle after 10-Gy irradiation, while no arrest
was obtained after irradiation of X17LoVo cells with a mutated
p53. The HT29 (MSI–/mutp53) cell line was similarly transfected
with a wtp53 expression vector and a subclone HT29A3 was
selected using geneticin as described above; HT29A3 had inte-
grated the plasmid in chromosome 12 (12q11–q12), as evidenced
by FISH. HT29A3 was arrested in the G1 phase after inhibition of
pyrimidine synthesis, as published by Soulié et al (1999), while no
arrest was obtained with HT29 parental cells, showing the domi-
nant function of wtp53 in the HT29A3 cell line. The four cell lines
were established as transplantable tumours (s.c. injection of 2 ´
106 cells). A summary of the clinical and biological information
about CRCs and cell lines is given in Table 1.
Mononucleotide repeat microsatellite analysis
The MSI phenotype was determined by multiplex polymerase
chain reaction (PCR) amplification of three microsatellite
markers: BAT-26, as described (Hoang et al, 1997), BAT-25 and
BAT-RII as described (Zhou et al (1998).
Detection of p53 mutations in CRCs
Characterization of the TP53 gene was conducted according to the
two-step procedure of (Hamelin et al, 1993).
Mice
Eight- to 10-week old, 25–30 g body weight, swiss nu/nu male or
female mice, bred in the animal facilities of the Curie Institute,
Paris, France were used in these assays. The animals were main-
tained under specified pathogen-free conditions. Their care and
housing were in accordance with the institutional guidelines of the
French Ethical Committee (Ministère de l’Agriculture et de la
Forêt, Direction de la Santé et de la Protection Animale, Paris,
France) and under the supervision of authorized investigators.
Growth inhibition studies
Mice were grafted with tumour fragments of approximately 
15 mm3 volume. Mice bearing growing tumours with a volume of
300–500 mm3 were individually identified and randomly assigned
to the control or treated group and the treatment started. The
animals bearing tumours were sacrificed when their tumour
volume reached 2000 mm3, defined as ethical sacrifice. Volumes
of individual tumours were calculated from the measurements of
two perpendicular diameters using a calliper, performed every 2
days. Each tumour volume (V) was calculated according to the
following formula: V = a2 ´ b/2, where a and b are the smallest and
largest perpendicular tumour diameters. Relative tumour volumes
were calculated form the formula: RTV = (VX/V1), where VX = the
volume on day x and V1 is the tumour volume at the initiation of
therapy (day 1). Growth curves (Figure 1) were obtained for each
individual tumour by plotting values of RTV against time
(expressed as days after the start of treatment). The anti-tumour
activity was evaluated according to four criteria: (i) the growth
inhibition (GI), which was calculated according to the following
formula: % GI = 100-(RTVt/RTVc) ´ 100 where RTVt is the mean
RTV of the treated group and RTVc that of the control group, at
the time of sacrifice of the first mouse in the group control when it
attained a tumour volume of 2000 mm3; (ii) the growth delay was
calculated as the time necessary to increase of fivefold the tumour
volume of individual mice. The cumulative percentage of indi-
vidual tumours (mice) reaching this 53-relative volume increase
is plotted as a function of time on Figures 2 and 3. This corre-
sponds to the survival time of mice. Statistical significance of the
differences between the individual growth delays was tested by a
log-rank test; (iii) a relative growth delay was calculated as the
difference between the time in days required for control and
treated tumours to reach a fivefold increase in volume (Houghton
et al, 1995). A ratio between the growth delays of tumours in the
treated group and that of the control group was also calculated and
reported on Tables 2 and 3; and then (iv) the number of partial
responses or complete tumour regressions (PR and CR); PR was
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defined as tumour growth inhibition greater than 50% and CR as
tumours that had regressed and could no longer be palpated. Mice
were considered to be cured if tumour-free after 180 days of obser-
vation.
Formulation and administration
CPT-11 (Campto®, Irinotecan) was generously supplied by Rhône
Poulenc Rorer (Vitry sur Seine, France). Stock solution of CPT-11
was diluted in 0.9% sodium chloride solution and administered i.p.
in a 0.2ml volume to tumour-bearing mice using an intermittent
schedule: two doses were tested, a high total dose of 240mg kg–1
(6 injections of 40mg kg–1 day–1 every 4 days) and a total low dose
of 40mg kg–1 (four injections of 10mg kg–1 day–1 every 4 days).
Mice in the control groups received 0.2ml of the drug-formulating
vehicle with the same schedule as given to the treated animals.
top-1, p53, mdr-1and fas-receptor PCR mRNA
expression
Isolation of total RNA from frozen tumour samples weighing
approximately 20mg was done as follows: the frozen tissue was
placed under liquid nitrogen and immediately pulverized with a
mortar and pestle. The pulverized tissue was rapidly transferred 
to 1ml-containing TRIZOL® Reagent (Gibco-BRL, Life
Technologies). The resulting RNA pellet was resuspended in 40ml
sterile deionized water, and stored overnight at 4°C for complete
dissolution. The concentration of the RNA was determined by
spectrophotometry.
Synthesis of complementary DNAs from poly-adenosine
(poly(A)) mRNA was done as follows: RNA at a final concentra-
tion of 2mg in 20ml of sterile water was incubated at 65°C for 
10min. A mix containing 4ml of 53RT buffer (Gibco-BRL, Life
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Figure 1Anti-tumoural effects of CPT-11 on human colorectal cancers established from clinical samples and subcutaneously grafted into the scapular area of
nudemice. Individual growth curves for TC1 (A, B, C), TC118m (D, E, F) and TC71 tumours (G, H, I). Tumour-bearing mice were treated with CPT-11 at low
dose (B, E, H) (10mg kg–1 at 4-day intervals ´4) or high dose (C, F, I) (40mg kg–1 at 4-day intervals ´6)916 RA Bras-Gonçalves et al
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Technologies), 2 ml dithiothreitol (DTT) (100 mM), 1 ml of oligo-
dT (200 ng ml–1), 1 ml of a mix containing 12.5 mM of each dNTP
(final concentration 2.5 mM) and 0.2 ml (200 U ml–1) of RNAase H
reverse transcriptase (Gibco-BRL, Life Technologies) was added
to the RNA and incubated at 45°C for 60 min.
PCR primers
The primers listed below were selected for their specificity and
their selectivity towards human gene sequences (purchased from
Oligo Express, Paris).
top1-1: S 5¢-AAA AGT CCA AGC ATA GCA ACA G-3¢
(bases 345–365 of the topoisomerase-1 gene coding sequence)
top1-2: AS 5¢-AGG AAC AAA ATA GCC ATC ATC T-3¢
(bases 574–595 of the topoisomerase-1 gene coding sequence)
mdr1-1: S 5¢-AGC GCG AGG TCG GGA TGG ATC TTG
AAG GGG A-3¢ (bases 411–441 of the mdr-1 gene coding
sequence (Murphy et al, 1990))
mdr1-2: AS 5¢-TTG ACA TCA GAT CTT CTA AAT TTC
CTG CAT TT-3¢ (bases 664–695 of the mdr-1 gene coding
sequence (Murphy et al, 1990))
p53-1: S 5¢-ACA CGC TTC CCT GGA TTG G-3¢ (bases
168–186 of the p53 gene coding sequence (el-Mahdani et al,
1997))
p53-2: AS 5¢-GGT CTT GGC CAG TTG GCA A-3¢ (bases
616–634 of the p53 gene coding sequence (el-Mahdani et al,
1997))
fas R-1: S 5¢-CAA GTG ACT GAC ATC AAC TCC-3¢ (bases
 
Figure 3 Effect of CPT-11 on the survival of mice bearing human colorectal
cancers established from the cell lines HT29 and HT29A3, a subclone of
HT29 transfected with a dominantly expressed wtp53. Survival curves are
plotted as a function of the survival time of mice, which were sacrificed as
their tumour reached 2000 mm3. Mice were treated with CPT-11 at low dose
(A) (10 mg kg–1 day–1 at 4-day intervals ´ 4) or high dose (B) (40 mg kg–1 at
4-day intervals ´ 6). P-values (log-rank test) corresponding to the differences
between the growth curves of CPT-11 treated HT29 and HT29A3 tumours,
are indicated
Table 1 Clinical characteristics of the CRC tumours and cell lines used
Tumours Origin Stagea HNPCC
TC1 Rectum B No
TC124m Liver metastasis D No
TC118m Liver metastasis D No
TC7fal Right colon C No
TC71 Sigmoid B Yesb
LoVo and X17LoVoc Lymph node metastasis D No
HT-29 and HT29A3d Sigmoid B No
aAccording to Duke’s classification. bWith a familial story of HNPCC.
cSubclone of LoVo cells transfected with Ala273-mutp53 expression vector.
dSubclone of HT29 cells transfected with wtp53 expression vector.
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Figure 2 Effect of CPT-11 on the survival of mice bearing human colorectal
cancers established from the cell lines LoVo and X17LoVo, a subclone of
LoVo transfected with a dominant mutp53. Survival curves are plotted as a
function of the survival time of mice, which were sacrificed as their tumour
reached 2000 mm3. Mice were treated with CPT-11 at low dose (A) 
(10 mg kg–1 at 4-day intervals ´ 4) or high dose (B) (40 mg kg–1 at 4-day
intervals ´ 6). P-values (log-rank test) corresponding to the differences
between the growth curves of CPT-11 treated LoVo and X17LoVo tumours,
are indicatedSensitivity to CPT-11 and genetic alterations of colorectal tumours 917
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270–290 of the fas-apo-1 receptor gene coding sequence
(Laurence et al, 1996))
fasR-2: AS 5¢-CCT TGG TTT TCC TTT CTG TGC-3¢ (bases
797–817 of the fas-apo-1 receptor gene coding sequence
(Laurence et al, 1996))
hprt-1: S 5¢-CAA CAG GGG ACA TAA AAG TAA T-3¢
(bases 414–435 of the hprt-gene coding sequence)
hprt-2: AS 5¢-AGT CCG TCA TAT TAG GTT TCT-3¢ (bases
534–554 of the hprt-gene coding sequence).
PCR conditions
The final PCR reaction volume was 50 ml: 1 ml (1/20) of the cDNA
solution was mixed with 5 ml of 103 Taq buffer (Appligene-
Oncor, Illkirch, France), 1 ml dNTP (final concentration 2.5 mM
each), 1 ml of each of the 5¢ and 3¢ primers (100 ng ml–1), 40.5 ml
water and finally 0.5 ml (2.5 U) Taq polymerase (Appligene-
Oncor, Illkirch, France) was added. After preheating at 94°C (hot-
start), the tubes were placed in a Perkin-Elmer 2400 thermocycler
Table 2 p53 status, MSI phenotype and responses to CPT-11 of CRC xenografts in nude mice established from clinical samples
CPT-11 Growth rate Growth Growth Nb Nb Nb Nb
Tumour p53 MSI total (days)a inhibition delay in mice PRd CRe curesf
xenografts dosage mean ± %b (days) days (ratio)c per
mg kg–1 group
TC1 wt – 0 23 ± 88
40 22 ± 10 0 0 8 3 0 0
240 54 ± 12** >99 (30) 31 (2.3) 8 5 3 0
TC124m wt –0 1 1   ± 36
40 21 ± 4** >99 (20) 10 (1.9) 7 7 0 0
240 31 ± 6** >99 (20) 20 (2.8) 7 4 3 0
TC118m wt –0 6   ± 18
40 41 ± 8*** >99 (17) 35 (6.8) 8 4 4 0
240 86 ± 13*** 100 (17) 80 (14) 8 8 0
TC7fal wt +0 8   ± 38
40 27 ± 3*** >99 (17) 19 (3.4) 9 5 4 0
240 44 ± 6*** >99 (17) 36 (5.5) 9 5 4 0
TC71 wt/mut +0 7   ± 21 0
40 15 ± 9* >99 (24) 8 (2.1) 6 6 0 0
240 86 ± 17*** 100 (24) 79 (12.3) 10 10 7
aDelay in days to reach a fivefold increase of CRC xenograft volume from their initial size at the start of treatment (300–500 mm3). bGI: treated/control growth
inhibition, calculated at the day (in parentheses) of the ethical sacrifice of the first control mouse bearing a tumour with a volume of 2000 mm3. cIn parentheses,
ratio between growth delays of the tumours in the treated group and that of the controls. dUp to 50% of growth inhibition, calculated at the ethical sacrifice of the
first control mouse. eComplete regressions. fTumour free mice were defined as bearing non palpable tumour after the end of the experiment (180 days).
gSignificantly different from control groups: *0.01 < P < 0.05; **10–6 < P < 10–4; ***P < 10–7.
Table 3 Responses to CPT-11 treatment of CRC cell lines varying for their p53 status and MSI phenotype established as xenografts in nude mice
CPT-11 Growth Nb Nb Nb Nb
Tumour p53 MSI total inhibition mice PRd CRe curesf
xenografts dosage %b (days) per
mg kg–1 group
LoVo wt +0 7
40 60 (8) 7 6 0 0
240 80 (8) 7 7 0
X17LoVo wt/muth +0 7
40 30 (7) 5 2 0 0
240 50 (7) 6 4 0 0
HT29 mut –0 1 0
40 31 (22) 9 2 0 0
240 66 (22) 9 7 0 0
HT29A3 mut/wth –0 6
40 70 (20) 6 6 0
240 >99 (20) 6 4 2 0
aDelay in days to reach a fivefold increase of CRC xenograft volume from their initial size at the start of treatment (300–500 mm3). bGI: treated/control growth
inhibition, calculated at the day (in parentheses) of the ethical sacrifice of the first control mouse bearing a tumour with a volume of 2000 mm3. cIn parentheses,
ratio between growth delays of the tumours in the treated group and that of the controls. dUp to 50% of growth inhibition, calculated at the ethical sacrifice of the
first control mouse. eComplete regressions. fTumour free mice were defined as bearing non palpable tumour after the end of the experiment (180 days).
gSignificantly different from control groups: *0.01 < P < 0.05; **10–6 < P < 10–4; ***P < 10–7. hDominant p53 in transfected lines.918 RA Bras-Gonçalves et al
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(Yvelines, France) for 3 min at 94°C followed by a maximum of
35 cycles (1 min at 94°C, 1.5 min at 60°C and 2 min at 72°C), and
a final elongation at 72°C for 7 min.
Quantitation of the PCR products
The linear range of amplification for each cDNA was established,
according to a kinetic analysis (Köhler et al, 1995); 7 ml of the
PCR products were consecutively pipetted at the end of each
chosen cycle number within a preliminary chosen range of 10–15
cycles, the final elongation at 72°C for 7 min being performed
immediately after, and stored at 4°C. Four microlitres of a gel
loading solution (bromophenol blue and xylene cyanol) were
added and the solution was electrophoresed on a 1.8% agarose gel
stained with ethidium bromide (final concentration of 0.5 mg ml–1).
After running 50 min at 100V, the gel was washed in distilled
water and placed on a UV illuminator (Imager, France) for a 6/30 s
exposure, the image was then processed by software NIH image
1.60 version. These conditions were rigorously used in all experi-
ments.
As the amplified PCR product is proportional to the initial
amount of DNA only in the linear phase of the amplification reac-
tion, we defined the linear range of expression for each gene. To
calculate the relative expression of the genes of interest, a ratio
was calculated between the fluorescent signal given by the BET-
intercalated PCR product within the linear amplification range of
the gene of interest and that given by that of the hprt gene.
RESULTS
Response to CPT-11 of human colorectal cancers
xenografts varying for their MSI phenotype
Five CRC tumours obtained from clinical samples were used and
established as xenografts. They originated from the left part of the
colon or from the rectum. Their staging differed, stage B, B and C
for TC1, TC71 and TC7fal respectively, and stage D for TC124m
and TC118m. The TC71 tumour originated from a patient with a
clinical history of hereditary non polyposis colon cancer (HNPCC)
(Table 1). All had a functional p53, including the TC71 which was
heterozygote with a mutation at the codon 176. The p53 status was
determined by DGGE for TC118m and TC124m and has been
previously described for TC1, TC7fal and TC71 (Hamelin et al,
1993; Cottu et al, 1996). These CRCs differed in their MSI pheno-
type, three being MSI– (TC1, TC124m and TC118m) and 2 MSI+
(TC7 and TC71). Microsatellite instability of tumours was
measured by band shift of three probes (BAT 25, BAT 26 and BAT
RII), as described by Olschwang et al (1997) (Table 4).
CPT-11 at a total dose of 240 mg kg–1 (high dosage) given as six
i.p. injections of 40 mg kg–1 at 4-day intervals was well tolerated.
CPT-11 was also given at a total dose of 40 mg kg–1 (low dosage)
as four injections of 10 mg kg–1 at 4-day intervals. The responses
of the five CRC tumours established from clinical samples to both
CPT-11-treatment protocols are summarized in Table 2. Without
treatment, the growth rates of CRC xenografts varied between 6
and 23 days for TC118m and TC1 respectively. Given at a high
dose, CPT-11 caused significant growth delays of all CRCs: 
31, 20, and 36 days for TC1, TC124m and TC7fal respectively,
representing 2.3-, 2.8- and 5.5-fold decreases in growth rate
respectively. Impressive growth delays were observed for
TC118m and TC71, up to tenfold their control growth rate.
Complete regressions produced by CPT-11 at high dosage were
observable in all CRC tumour models, with the CR frequency
varying from 3/8 to 10/10 for TC1 and TC71 respectively. Cures
were observed only in the group of TC71 tumours, with a
frequency of 70% (7/10): no palpable tumours at day 180 after
start of the treatment and histological examination of the graft site
revealed fibrosis tissue and the absence of remaining living
tumour cells.
At low dosage, CPT-11 caused a growth delay of 35 days for
TC118m, the effect was less marked for TC124m, TC7fal and
TC71 and absent for TC1. Complete regressions were observable
in TC118m and TC7fal, with the PR frequency varying from 3/8 to
6/6 for TC1 and TC71 respectively. All tumours regrew.
Individual growth curves of TC1, TC118m and TC71 in the
control, low and high dose CPT-11 groups are shown in Figure 1.
They allow the variability of drug responses in individual mice to
be evaluated for the three CRC models. TC1 was the least aggres-
sive of the three CRC, and mice survived 40 days in the control
group. CPT-11 at low dose did not modify TC1 tumour progres-
sion. At high dose, all eight TC1 tumours were slowed down and
three complete regressions were observed. No mice survived
beyond day 90 after start of treatment. TC118m grew very rapidly
in the control group and no mice survived beyond day 20. All
TC118m-bearing mice responded to CPT-11 at low dose, with four
complete regressions; at high dose, all had regressed completely at
day 20. However, all regrew between days 50 and 80. Their
growth rate was similar to that of untreated tumours. The growth
rate of TC71 tumours was intermediate, all mice survived 30 days
in the control group. The efficacy of CPT-11 at low doses was
variable. With high dose CPT-11, complete regressions of all the
tumours were induced and seven of ten TC71-bearing mice were
cured. No acceleration of growth rate was detected in the relapses.
Considering all the parameters of responsiveness, all these p53wt
colorectal cancer xenografts respond to CPT-11, with variable
sensivity; TC1(MSI–) was the least sensitive CRC and TC71
(MSI+) the most sensitive, as it was curable by high dose CPT-11.
Influence of p53 mutation on the response to CPT-11 of
xenografted CRC established from MSI+ cell lines
In order to evaluate the role of p53 mutation in CPT-11 response of
CRC xenografts, a MSI+ cell line (LoVo) was transfected with a
mutated p53 vector. The LoVo cell line was derived from a lymph
node metastasis of a CRC. LoVo cells were MSI+ with a homozy-
gous deletion of hMSH2 (Casares et al, 1995) and had a wild-type
p53 (Hamelin et al, 1993). Microsatellite instability of tumours
was measured by band shift of three probes (BAT 25, BAT 26 and
BAT RII), as described by Olschwang et al (1997) (Table 5). LoVo
cells were transfected with an Ala273-mutp53 geneticin resistance
expression vector, as described (Pocard et al, 1996), and one
subclone, X17LoVo, was selected and established as a xenograft in
nude mice.
LoVo and X17LoVo established as s.c. tumours were trans-
planted into mice for testing their sensitivity to CPT-11. The
growth rates of LoVo and X17LoVo were very similar, of 6 and 7
days respectively (data not shown). Given at high dose, CPT-11
caused growth inhibitions of 80% and 50% observed for LoVo and
X17LoVo respectively, but neither xenograft showed complete
regression with high dose CPT-11. Given at low dose, CPT-11
caused growth inhibitions of 60% and 30% for LoVo and
X17LoVo respectively, were observed. No complete regressionsSensitivity to CPT-11 and genetic alterations of colorectal tumours 919
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were achieved. Kinetics of the number of tumours (as a cumulative
percentage of the total number of mice per group) reaching indi-
vidually a fivefold increase of their initial volume at the start of the
treatment, were reported on Figure 2, as a function of time. This
parameter corresponds to the survival time of mice, which were
sacrificed as their tumour reached 2000 mm3. This parameter did
not differ between the two control groups of non-treated tumours
(LoVo and X17LoVo, P = 0.07) and data were pooled. Figure 2
visualizes the loss of sensitivity of X17LoVo tumours, at low
dosage (Figure 2A) as well as at high dosage (Figure 2B).
Differences between LoVo and X17LoVo were statistically signif-
icant, as calculated by the log-rank test (P = 0.05 and P = 0.0004),
for low dose and high dose experiments respectively. Taking into
account the different parameters of responsiveness to CPT-11,
X17LoVo (mutp53) tumours were less sensitive than LoVo
(wtp53) xenografts.
Influence of wtp53 on the response to CPT-11 of CRC
xenografts established from MSI– cell lines
The HT29 cell line was derived from a sigmoid colon cancer of
stage B1. HT29 cells were MSI– and had a mutated p53 in Ala 273
codon, as checked by us and published by Hamelin et al (1993)
respectively. Microsatellite instability of tumours was measured as
specified (Table 5). HT29 was transfected with a wtp53 geneticin
resistance expression vector, according to the methods described
in Pocard et al (1996). A selected subclone, HT29A3, had inte-
grated the plasmid in chromosome 12 (12q11–q12), as evidenced
by FISH. After inhibition of DNA synthesis, HT29A3 cells were
arrested in G1/S, while HT29 cells did not (data not shown). All
cell lines were tumorigenic, with 100% tumour takes in our exper-
imental conditions. The growth rates of HT29 and HT29A3
tumours did not significantly differ (of 8 and 10 days respectively
P = 0.25). Given at high dose, CPT-11 caused growth inhibitions
of 66 and 100% respectively. None of the HT29 xenografts
regressed completely under treatment, whereas two of six
HT29A3 achieved complete regression. Given at low dose, CPT-
11 caused growth inhibitions of 31% and 70% for HT29 and
HT29A3 tumours respectively. No complete regression was
achieved. All HT29A3 responded at least partially to the treat-
ment, whereas only two of the nine HT29 tumours were slowed
down. Individual growth delays of HT29 tumours as calculated as
the percentage of tumours (mice) reaching a fivefold increase of
the initial tumour volume at the start of the treatment, were
reported on Figure 3. Curves corresponding to the survival of non-
treated tumours (HT29 and HT29A3) did not significantly differ
(P = 0.25) and data were pooled. Figure 3 visualizes the prolon-
gated survival of mice bearing the HT29A3 tumours as compared
to that bearing the HT29 tumours, at low dosage (Figure 3A) as
well as at high dosage (Figure 3B). These differences were statisti-
cally different, as calculated by the log-rank test (P = 0.0001 and
P = 0.0002), for low dose and high dose treatments respectively.
Taking into account the different parameters of responsiveness to
CPT-11, HT29A3 tumours, wtp53 transfected, were more sensitive
than tumours established from HT29, its parental mutp53 cell line.
top1, fasR, mdr1 and p53 gene expression in CRC
xenografts
Relative expressions of the top1, fasR, mdr1 and p53 genes were
determined with respect to the hypoxanthine phosphoribosyl trans-
ferase (hprt) gene, chosen as the internal standard. The hprt gene
was expressed at a constant level among the different specimens
(Figure 4). The relative expression of the genes of interest was
calculated within the linear amplification range of the gene of
interest and that given by that of the hprt gene (Figure 5). There
was little variation of top1 gene expression between the different
tumours. A fourfold variation of top1 expression among the
different tumour samples was found (Table 3). Expression of mdr1
showed a variation of greater than 80-fold in CRC xenografts, in
the conditions described here. These large variations in mdr1 gene
expression were due to exceptionally high values in primary
tumours and very low values in metastatic tumours. p53 gene
expression was very high in X17LoVo mutant tumours,
100-fold higher than its parental LoVo cell line. The level of
expression of p53 varied over a tenfold range among the other
tumours. fasR expression showed a 20-fold variation. top1, mdr1,
p53 and fasR mRNA levels did not correlate with responsiveness
of xenografts to CPT-11 (Table 6).
DISCUSSION
We have tested here the sensitivity to CPT-11 of a panel of nine
human colorectal cancers (CRC) differing with respect to their
genetic alterations concerning p53 function and/or DNA repair,
hypothesizing that these genetic alterations influence their
response to CPT-11. This might thereby orientate towards identifi-
cation of groups of patients who could benefit from top1
inhibitors. CRC xenografts used here originated either from
clinical CRC samples (without any intermediate cell culture) or
from CRC cell lines, which have been experimentally modified 
for p53 status.
Among the xenografts established from clinical samples, two
were MSI+ and three were MSI–, all were associated with a func-
tional p53 and their responses to low or high dose CPT-11 were
compared. At high doses, differences between the responses of the
CRCs were seen: both MSI+ tumours were highly sensitive, one
(TC71) being curable in 70% of cases. The three MSI– CRCs
Table 4 MSI phenotype and p53 status of the CRC tumours
MSI phenotype p53 status
Tumours BAT-26 BAT-RII BAT-25 mutated codon
TC1 – – – wt
TC124m – – – wt
TC118m – – – wt
TC7fal Band shift Band shift Band shift wt
TC71 Band shift Band shift Band shift 176/heterozygote920 RA Bras-Gonçalves et al
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responded to high doses of CPT-11, but with only moderate
responses for two of them (TC1 and TC124m). At low doses, one
MSI– tumour (TC1), did not respond at all; the four other CRC
xenografts (MSI+ or MSI–) were responders, and one (TC118m)
was highly sensitive to CPT-11 with four CR of eight mice, but
none were cured by CPT-11. Growth rate slopes of recurrences
were similar to that of the controls. The sensitivity of CPT-11
treated tumours (TC118m) to subsequent treatment with CPT-11
was not diminished (data not shown).
To test the respective role of MSI and p53 in the response to
CPT-11, MSI+ or MSI– tumour cell lines were used. The HT29 cell
line is MSI–/mutp53 and resistant to CPT-11 at low dose, although
at high dosage a mean growth inhibition of 66% could be obtained.
HT29A3 is a tumorigenic subclone of HT29 cells transfected with
wtp53. The transfected plasmid was located in chromosome 12
and dominant function of wtp53 was attested to by arrest of the cell
cycle when HT29A3 growth was inhibited by an inhibitor of
pyrimidine synthesis. Transfection of wtp53 in HT29 did not slow
their growth in control mice and clearly increased their sensitivity
to CPT-11, prolongating the survival of tumour-bearing mice,
namely when treated at high dosage.
The LoVo cell line has a MSI+ phenotype (Malkhosyan et al,
1996) and a wtp53. Its subclone, X17LoVo, was selected for high
expression of mutp53 which behaved like a dominant mutated p53
conferring a gain of function, as described in other models
(Gualberto et al, 1998). g-irradiation did not induce cell cycle
arrest in G1/S (Pocard et al, 1996). Expression of mutp53 in
X17LoVo led to a reduction of sensitivity as compared to LoVo as
shown by reduced growth delay and decreased growth inhibition,
and shortening their survival time.
Taken together, these results show that among the three MSI+
(TC7Fal, TC71 and LoVo) xenografts, all were sensitive at both
dosages excepted LoVo which responded only at high dosage.
Among the four MSI–-CRC xenografts (TC1, TC118m, TC124m
and HT29), one (HT29) was completely refractory to both
dosages, and another (TC1) to low dosage only; the two others
(TC118m and TC124m) displayed a high sensitivity whatever the
dosage used. In both types (MSI+ or MSI–) mutation of p53 was
also associated with a lack of responsiveness, which can be over-
come by re-expression of wtp53.
In recent years, it has been proposed that genotypic alterations
acquired during tumour progression may provide additional prog-
nostic information. In colorectal cancers, a correlation between
survival, 17p allelic losses and/or p53 mutations has been estab-
lished (Hamelin et al, 1994). Tumour prognosis is determined
either by intrinsic aggressiveness and/or the potential sensitivity to
chemotherapy. The p53 point mutations seem to be crucial in these
two parameters, at least in colorectal cancers; indeed p53-deficient
tumours are more invasive and less responsive. Goh et al showed a
shortened survival of mutp53 CRC patients with post-operative
therapies as compared to patients with CRCs with a functional p53
(Goh et al, 1995). This confirmed the study by Lowe showing that
p53 plays a role in determining responsiveness to adjuvant
chemotherapy (Lowe et al, 1994). Unresponsiveness of p53-defi-
cient tumours has been ascribed to lack of apoptosis normally
induced after G1/S-arrest following chemotherapy. Besides this
clearly described programmed cell death, other alterations of cell
cycle checkpoints in p53 deficient cells have been reported. By-
passing of the G2/M arrest in p53-deficient cells after drug treat-
ment drives them either to survive or die, probably depending on
the accumulation of DNA lesions (Kastan et al, 1991; Ceraline et
al, 1998), and this is independent of the induction of apoptosis
(Attalla et al, 1997).
Different combinations of genetic alterations lead to different
pathways of CRC progression. In a series of 87 CRCs, Olschwang
et al found 41 MSI-/mutp53 (47%), nine MSI+/wtp53 (10%), four
MSI+/mutp53 (4.5%) and 33 MSI–/wtp53 (Olschwang et al, 1997).
Fifteen per cent of CRCs were MSI+ and more often associated
with a wtp53. Fifty per cent had a p53 mutation and were rarely
associated with a MSI phenotype. This inverse correlation was
also found in CRC cell lines (Cottu et al, 1996). Sporadic MSI+
CRCs and HNPCC have a better prognosis than cancers with MSI
(Bubb et al, 1996; dos Santos et al, 1996; Vaurs and Bignon, 1997;
Lukish et al, 1998) and reviewed by Arnheim and Shibata (1997).
Their low progression potential is illustrated by the low frequency
of MSI+ liver metastases (Ishimaru et al, 1995).
Advances in adjuvant chemotherapy of colorectal cancers must
address a complex series of factors including not only the avail-
ability of new effective compounds but also which subgroups of
patients may benefit from them. Inhibitors of topoisomerase 1 are
a new category of putatively potent anti-tumour agents. CPT-11 is
a water soluble analogue of camptothecin, which is metabolized to
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Table 5 MSI phenotype and p53 status of the cell lines used
MSI phenotype p53 Status
Cell lines BAT-26 BAT-RII BAT-25 Mutated Codon
LoVo –a Band shift Band shift wt
X17LoVo –a Band shift Band shift 273mut transfected
HT29 – – – Ala273
HT29A3 – – – wtp53 transfected
aHomozygous deletion of hMSH2.
Figure 4 Comparison of the linear amplification range of top1 and hprt
gene mRNA expression in the CRC samples. hprt mRNA expression
(internal standard) as a function of the number of amplification cycles
(1, X17LoVo; 2, LoVo; 3, HT29; 4, HT29A3; 5, TC1; 6,TC7fal; 7, TC71; 8,
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an active compound, 7-ethyl-10-hydroxycamptothecin (SN38)
b-glucuronide, by a carboxylesterase (Rivory et al, 1996). CPT-11
toxicity is a limiting factor (Armand et al, 1996). This contrasts
with the tolerance in mice. Progresses in overcoming CPT-11 toxi-
city in humans should improve the clinical use of this compound
(Takasuna et al, 1995, 1996). Nevertheless, even at the moderate
doses tolerable by human hosts, top1 inhibitors are active agents in
patients with metastatic colorectal cancers (Conti et al, 1996;
Pazdur et al, 1997) and reviewed in Rougier and Bugat (1996);
Rothenberg (1997).
CRC xenografts displayed a large range of sensitivity to CPT-
11, from resistance to eradication. These differences were not due
to different levels of top1, as evaluated by a semiquantitative
method (Murphy et al, 1990), as already published (Goldwasser et
al, 1995; van Ark-Otte et al, 1998). Jansen et al (1998) proposes a
role for P-glycoprotein (encoded by mdr1 gene) in lack of efficacy
of numerous compounds, including CPT-11. Our study did not
support such a role as no correlation was found between P-glyco-
protein encoding gene expression (MDR1) and CPT-11 responses
and, furthermore, a diversity of mdr1 gene expression (a range of
80-fold) in our series of CRCs was shown.
The apoptotic process induced by drugs can involve the fas
receptor pathway (Micheau et al, 1997) and it has been described
that many CRCs express the fasR and initiate the death programme
when activated (Meterissian et al, 1997; Tillman et al, 1998). Is
CPT-11 activity mediated by activation of the fasR pathway in
vivo, as shown in vitro in the HT29 cell line by Shao et al (1998)?
In our series, HT29 tumours were the most CPT-11-resistant and
they expressed a relatively low level of fasR, similar to that of
HT29A3, its CPT-11-responsive counterpart, this excluding such
correlation.
It was published that sensitivity to CPT-11 depends on the accu-
mulation and stability of cleavable complexes, and this could be a
parameter explaining the inter tumour differences. Cleavable
complex levels were measured in vivo after camptothecin treat-
ment in colon carcinoma cell lines by Goldwasser et al who
showed a direct correlation between levels of cleavable complexes
and cytotoxicity (Goldwasser et al, 1995). This has not been tested
in vitro in our study as the methodology is in the process of being
developed for in vivo samples but is not presently available.
In conclusion, our results indicate that CRCs are good candi-
dates for CPT-11 chemotherapy whatever their MSI phenotype as
long as they have a wild-type p53, whereas some, but probably not
all mutations of p53, have the propensity to overcome CPT-11
sensitivity.
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